Bhutan sells $60M Bitcoin but keeps $1.4B stake
The Royal Government of Bhutan sold nearly $60 million worth of Bitcoin (CRYPTO:BTC) over four days in July, according to on-chain data from Arkham Intelligence.
Between July 10 and July 14, Bhutan transferred 512.84 BTC across six transactions, mainly to the Binance exchange.
One transfer alone moved 208.56 BTC, valued at approximately $23.18 million.
The overall sales amounted to about $59.47 million, coinciding with Bitcoin reaching new price highs.
Despite these sales, Bhutan continues to hold a significant crypto treasury of 11,411 BTC, valued at around $1.4 billion at current prices.
Arkham’s data shows the country’s crypto holdings increased from $1.29 billion to $1.37 billion within a week, buoyed by Bitcoin’s 12.4% price rise from $108,000 to $122,000.
Bhutan’s Ethereum holdings remained steady at 656 ETH, worth approximately $1.93 million after an 18% price increase.
These moves suggest active portfolio management, trimming Bitcoin exposure during price surges while allowing overall gains to accumulate.
The strategy could reflect Bhutan’s intent to maintain liquidity and manage risk amid Bitcoin’s known volatility, balancing immediate profits with long-term asset value.
Earlier, between July 3 and July 10, Bhutan’s Bitcoin balance rose from $1.26 billion to $1.30 billion even after transferring 213 BTC to Binance.
Market conditions saw Bitcoin consolidate between $105,000 and $108,000 before surging past $121,000 on July 13, coinciding with Bhutan’s largest Bitcoin sell-off.
Notably, the US imposed new tariffs on the EU and Mexico around the same time, events that might have unsettled risk assets in prior cycles.
At the time of reporting, Bitcoin price was $117,637.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

Crypto: In 2026, BNB Chain Emerges as the Global Leader in RWA Growth

BlackRock Bitcoin ETF outflows hit $19.23M as sector sheds $463M in four days
Pi Network Price Prediction: Can PI Hold Its Wedge Breakout Before the Upgrade?

